

A

PATENT ATTORNEY DOCKET NO.: 44481-5017-03

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents **BOX PATENT APPLICATION** Washington, D.C. 20231

PRIOR APPLICATION:

Examiner: P. Gambel

Group Art Unit: 1806

## CONTINUATION, DIVISIONAL, AND CONTINUATION-IN-PART PATENT APPLICATION TRANSMITTAL UNDER 37 C.F.R. § 1.53(b)

This is a request for filing a patent application under 37 C.F.R. § 1.53(b).

This application is a [X]Continuation [ ] Divisional [ ] Continuation-in-Part 1. patent application under 37 C.F.R. § 1.53(b), of pending prior application no. 08/258,283, filed on June 10, 1994, of RAMAKRISHNAN et al, entitled INHIBITORY IMMUNOGLOBULIN POLYPEPTIDES TO HUMAN PDGF BETA RECEPTOR 2. The papers enclosed are as follows: Page(s) of specification including: <u>49</u> Title Page 01 Page(s) of claims 03 Page of abstract 01 <u>13</u> Sheet(s) of drawings containing 12 Figures Other: 3. Amendments For continuation and divisional applications:

Cancel in this application original claims \_\_\_\_\_ in the enclosed copy of prior

application before calculating the filing fee.

[]

4.



### ATTORNEY DOCKET NO.44481-5017-03

Page 2

[]	A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)
Oat	n or Declaration
For	continuation or divisional applications:
[]	A newly executed (original or copy) oath or declaration is enclosed.
[ X]	A copy of an oath or declaration from a prior application is enclosed under 37 C.F.R. § 1.63(d). The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied is considered as part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
[]	A signed statement deleting inventor(s) named in the prior application is enclosed
For	continuation-in-part applications:
[]	A newly executed (original or copy) oath or declaration is enclosed.
[]	An oath or declaration is not enclosed. This application is being filed under 37 C.F.R. § 1.53(f). Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the declaration and paying the filing fees.
Rela	ate Back - 35 U.S.C. § 120
[X]	Amend the specification by deleting the continuing application information at page 2, lines 8-11 and inserting after "cross reference to related applications" the sentence:
	"This is a [X] continuation [ ] divisional [ ] continuation-in-part of copending application(s)

Application Serial No. 08/258,283 filed June 10, 1994, which is a

continuation-part of Application Serial No. 08/253,440 filed June 7, 1994,

[X]

5.



### ATTORNEY DOCKET NO.44481-5017-03

Page 3

	which is a continuation of Application Serial No. 07/801,795, filed December 2, 1991."  [ ] International Application No filed on and which designated the U.S."						
6.	intern	Priority - foreign applications under 35 U.S.C. § 119(a)-(d) or § 365(b) or PCT international applications under 35 U.S.C. § 365(a) designating at least one country other than the U.S.					
	[]	Priority of the fol	lowing foreign application(	s) is/are claime	d:		
	(	Country	Application No.		Filed		
	Certified copy(ies): [ ] is/are attached. [ ] will follow. [ ] was/were filed in prior U.S. Application Noon						
7.	Assignment						
	For continuation or divisional applications:						
	[X]	[X] The prior application is assigned of record to <b>COR THERAPEUTICS, INC.</b> , recorded August 15, 1994 at Reel/Frame 7102/0483.					
	[ ] An assignment of the invention to				and a ed.		
	For continuation-in-part applications:						
	[]	An assignment of	f the invention to		and a		

PTO Form-1595, Recordation Form Cover Sheet, are enclosed.

### 8. Fee Calculation (37 C.F.R. § 1.16)

CLAIMS FOR FEE CALCULATION				
	Number Filed	Number Extra	at Rate of	Basic Fee Utility \$790.00 Design \$330.00
Total Claims (37 C.F.R. § 1.16(c))	- 20 =		\$ 22.00 each =	+\$
Independent Claims (37 C.F.R. § 1.16(b))	- 3=		\$ 82.00 each =	+\$
Multiple dependent claim(s), if any (37 C.F.R. § 1.16(d)) \$270.00			+\$	
SUB-TOTAL =			\$	
Reduction by ½ for filing by a small entity			\$	
TOTAL FILING FEE =			\$	


### 9. Fee Payment

[]

# [X] Not Enclosed. NO FEE IS BEING PAID BY CHECK OR DEPOSIT ACCOUNT AT THIS TIME.

This application is being filed under the provisions of 37 C.F.R. § 1.53(f). Applicant(s) await notification from the Patent and Trademark Office of the time set for paying the filing fees.

Enclo	osed.
A che	eck(s) in the amount of \$ to cover the is enclosed.
[]	The fee for extra claims under 37 C.F.R. § 1.16(d) is not being paid at this time and no authorization is given to charge our deposit account for this fee.



- 13. [x] PETITION FOR EXTENSION OF TIME. If any extension of time is necessary for the filing of this application, including any extension in the prior application, application no. 08/258,283, filed June 10, 1994, for the purpose of maintaining copendency between the prior application and the present application, and such extension has not otherwise been requested, such an extension is hereby requested, and the Commissioner is authorized to charge necessary fees for such an extension to Deposit Account No. 50-0310.
- 14. [x] **EXCEPT** for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be an **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).



#### ATTORNEY DOCKET NO.44481-5017-03

Page 6

15.	Addi	Additional papers enclosed:			
	[]	Information Disclosur	e Statement		
	[ ]	Form PTO-1449,	references included		

Declaration of Biological Deposit

[ ] Submission of "Sequence Listing", computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

By:

Reid G. Adler

Registration No. 30,988

Dated: January 7, 1998 MORGAN, LEWIS & BOCKIUS LLP 1800 M Street, N.W. Washington, D.C. 20036 202-467-7000